Republic Healthcare Limited (8357) AI Stock Analysis

• Market Cap: HK$93.60M
• Dividend Yield: N/A
• Average Volume (3M): 136.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: -11.68%
• EPS Growth: -71.01%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Care Facilities
• EPS (TTM): -0.01
• Shares Outstanding: 624,000,000
• 10 Day Avg. Volume: 46,500
• 30 Day Avg. Volume: 136,000
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: ―

Republic Healthcare Limited shows financial stability with strong equity positions and low debt, but faces significant challenges due to declining revenues and losses. The technical analysis indicates the stock is overbought, which may lead to a correction. Valuation is a concern due to negative earnings, making the stock less attractive. Overall, while there are some operational improvements, the risks and valuation concerns limit the stock's appeal.

Republic Healthcare Limited Business Overview & Revenue Model

Company Description

Republic Healthcare Limited, a primary healthcare services company, provides consultation, medical investigation, and treatment services in Singapore. The company offers various treatment solutions for common medical conditions and focuses on sexual health and infectious diseases. It also provides treatment solutions for common skin conditions and basic medical aesthetics services. The company operates nine clinics under the Dr. Tan & Partners brand name; and one clinic under the S Aesthetics brand name. Republic Healthcare Limited was founded in 2010 and is headquartered in Singapore.

How the Company Makes Money

Republic Healthcare Limited generates revenue primarily through its provision of medical services. The company earns money by charging patients for consultations with general practitioners and specialists, as well as for various medical procedures and treatments offered at its facilities. Additionally, the company may have partnerships with healthcare providers and insurance companies, which can facilitate patient referrals and reimbursements, thus contributing to its earnings. Revenue can also be derived from ancillary services, such as diagnostic tests and preventive healthcare programs. These diversified revenue streams enable the company to maintain a stable financial performance.

Republic Healthcare Limited Financial Statement Overview

Summary

Republic Healthcare Limited demonstrates strong equity positions with low leverage, which provides financial stability. However, declining revenues and persistent net losses pose significant challenges. Operational improvements are visible, but sustained profitability remains a concern.

Income Statement

Revenue has declined over the past three years, with a negative revenue growth rate and shrinking gross profit margin from 72.1% in 2019 to 24.4% in 2024. The net profit margin is negative, indicating losses. However, the company improved its EBIT margin from negative to 18.42% in 2024, showing some operational efficiency.

Balance Sheet

The company maintains a strong equity position with an equity ratio consistently above 80%. Debt-to-equity ratio is low at 0.068, indicating low financial leverage. However, the return on equity is negative due to net losses, which presents a challenge for profitability.

Cash Flow

The free cash flow has fluctuated, with a decline in free cash flow growth rate in recent periods. The operating cash flow to net income ratio is positive, indicating operational cash generation despite accounting losses. However, the free cash flow to net income ratio is inconsistent, reflecting variability in capital management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.23M	10.00M	9.04M	13.37M	13.72M
Gross Profit	6.48M	6.83M	5.97M	9.13M	9.83M
EBITDA	-188.79K	29.34K	-387.88K	962.89K	1.43M
Net Income	-178.16K	-855.12K	-1.47M	-997.93K	65.90K
Balance Sheet
Total Assets	14.48M	15.64M	16.42M	19.27M	19.34M
Cash, Cash Equivalents and Short-Term Investments	11.52M	11.93M	11.83M	14.14M	13.07M
Total Debt	858.22K	961.16K	810.47K	1.55M	2.76M
Total Liabilities	1.93M	2.89M	2.30M	3.67M	6.09M
Stockholders Equity	12.55M	12.75M	14.12M	15.59M	13.26M
Cash Flow
Free Cash Flow	51.27K	806.24K	-1.16M	-1.13M	232.36K
Operating Cash Flow	125.07K	899.91K	-734.46K	-510.07K	771.30K
Investing Cash Flow	-93.94K	831.49K	-987.23K	-1.56M	7.62M
Financing Cash Flow	-531.65K	-587.62K	-689.73K	2.28M	-1.36M

Republic Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8357, the sentiment is Positive. The current price of 0.15 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.16, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.33 is Neutral, neither overbought nor oversold. The STOCH value of 47.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8357.

Republic Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$233.43M	9.76	10.72%	4.39%	-22.12%	-28.95%
Sector *	65 Neutral	¥341.84B	11.04	-0.17%	2.40%	9.73%	-9.93%
8357	60 Neutral	HK$93.60M	―	-10.31%	―	-11.68%	-71.01%
8307	52 Neutral	HK$88.08M	―	-44.60%	―	-8.20%	-10.39%
8143	51 Neutral	HK$135.28M	―	-18.22%	―	-58.63%	40.85%
8161	47 Neutral	HK$18.72M	2.32	105.83%	―	-8.48%	―
8437	44 Neutral	HK$9.86M	―		―	59.11%	48.09%